The U.S. Food and Drug Administration (FDA) is allowing Oxygen Biotherapeutics Inc. to resume patient testing on its experimental brain injury drug Oxycyte, nearly six years after the agency suspended clinical trials of the drug due to concerns about its use in patients with severe traumatic brain injuries (TBI). TBIs are caused by a blow to the head or a penetrating head injury and interfere with normal brain functioning. About 52,000 people die from TBI in the United States each year, according to the Brain Trauma Foundation. When someone suffers from a TBI his platelet count significantly drops in response ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.